大日本住友製薬 株式会社
Japanese only大日本住友製薬 株式会社
About this English name
No English name available. Original Japanese name is shown.
Enforcement records (3)
- Apr 27, 2020Administrative GuidanceAct on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical DevicesMinistry of Health, Labour and Welfare
Osaka Prefecture provided information that Daiichi Sankyo Company, Limited has begun voluntary recall of the following pharmaceuticals.
- Oct 5, 2017先駆け審査指定制度対象品目の募集薬事法Ministry of Health, Labour and Welfare
Unapproved Parkinson's disease treatment using non-self iPS cell-derived dopamine neural precursor cells
- Feb 28, 2017指定薬事法Ministry of Health, Labour and Welfare
This concerns Parkinson's disease treatment using non-autologous iPS cell-derived dopamine neural precursor cells, which have a different mechanism of action from conventional treatments. Although there is no clinical experience, non-clinical efficacy evaluations have reported significant symptom improvement (more than 40% in motor symptom scores) from six months after transplantation, as well as dopamine synthesis and reuptake activity (PET imaging) at the transplantation site in the brain.
Watch this company
Get an email when 大日本住友製薬 株式会社 has new enforcement actions or registry changes. Sign-in is via a one-time email link — no password required.
Language
日本語版を見る (Japanese)Registry data
- Status
- Active
For compliance use
This profile aggregates public Japanese government records. Always cross-reference the Corporate Number when matching this entity in your systems — Japanese English company names are often inconsistent across sources.